Three Renal Transplant Patients Developed Uveal Melanoma
A clinical study identified three kidney transplant recipients who developed rare uveal melanoma after immunosuppression.
Updated on Sept. 23, 2026 in Cancer
Three renal transplant patients were diagnosed with uveal melanoma following prolonged immunosuppression. Biopsies confirmed mixed-cell melanoma in all three individuals after microbiological testing for other causes returned negative results.
Why it matters
This report highlights a potential clinical challenge for transplant recipients, as prolonged immunosuppressive therapy can create unique oncological risks. Understanding these rare presentations is critical for monitoring long-term health in transplant populations.
The study observed three renal transplant patients over a follow-up period ranging from 6 to 83 months. The annual incidence rate of uveal melanoma in the general population is approximately 5.6 cases per million.
The details
The patients presented with specific variants, including two cases of choroidal melanoma and one of ciliary body melanoma, with one individual experiencing panuveitis and exudative retinal detachment. All patients underwent plaque brachytherapy to address the malignancies, with one additionally receiving photodynamic therapy.
Timeline
Patients were observed during a follow-up period ranging from 6 to 83 months.
The Big Picture
This case series informs the broader understanding of ocular oncology, aligning with diagnostic standards established by the Collaborative Ocular Oncology Group's uveal melanoma research protocols. It expands existing knowledge regarding the intersection of systemic immunosuppression and site-specific cancer development.
Transplant recipients should maintain routine ophthalmic screenings to identify potential ocular changes early. Patients experiencing sudden vision changes or inflammation after transplant surgery should promptly consult their specialized care team.
The takeaway
Clinicians managing transplant patients must remain vigilant for rare ocular symptoms that may arise due to long-term immunosuppression. Proactive monitoring remains the most effective strategy for managing potential complications in this specific patient demographic.
Further reading
For more information on the latest research and clinical standards, visit the Cancer section.
Source note: This article includes information reported by Nature.
